歌礼制药ASC30临床试验取得积极期中结果
3月31日，歌礼制药（01672）发布公告，宣布其小分子GLP-1R激动剂ASC30在美国进行的Ib期临床试验取得积极期中结果。该试验针对肥胖症患者进行，显示ASC30超长效皮下注射剂在患者中半衰期达到36天，支持每月一次或更低频率给药。这一结果为公司在肥胖症治疗领域的创新提供了有力支持。
根据此前披露的数据，接受ASC30口服片剂治疗的肥胖症患者在4周内体重下降6.3%。此次试验的结果显示，ASC30的三种超长效皮下注射制剂在耐受性和安全性方面表现良好，未报告严重不良事件，且肝酶指标未见升高。这些积极的试验结果使得ASC30有望成为同类最佳药物，进一步推动公司在该领域的研发进展。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10